¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adrenergic blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • depolarizing agent
    Å»ºÐ±ØÁ¦
  • diagnostic agent
    Áø´Ü½Ã¾à
  • diluting agent
    Èñ¼®Á¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • fibrinolytic agent
    ¼¶À¯¼Ò¿ëÇØÁ¦, ÇǺ기¿ëÇØÁ¦
  • germicidal agent
    »ì±ÕÁ¦
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • health care agent
    1. °Ç°­°ü¸®¿ä¿ø 2. °Ç°­°ü¸®±â±¸
  • ischemia-inducing agent
    ÇãÇ÷À¯µµÁ¦
  • induction agent
    À¯µµ¹°Áú, À¯µµÁ¦
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • lipotropic agent
    Ä£Áö¹æÁ¦
  • mucolytic agent
    Á¡¾×¿ëÇØÁ¦
  • mutagenic agent
    µ¹¿¬º¯ÀÌ¿ø
  • masking agent
    Â÷ÆóÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • dehydrating agent
    Å»¼öÁ¦
  • denaturizing agent
    º¯¼ºÁ¦
  • depolarizing agent
    Å»ºÐ±ØÁ¦
  • diagnostic agent
    Áø´Ü¾à
  • diluting agent
    Èñ¼®Á¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • fibrinolytic agent
    ¼¶À¯¼Ò¿ëÇØ¹°Áú
  • germicidal agent
    »ì±ÕÁ¦
  • health care agent
    °Ç°­°ü¸®¿ä¿ø, °Ç°­°ü¸®±â±¸
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • ischemia-inducing agent
    ÇãÇæÀ¯µµÁ¦
  • lipotropic agent
    Ä£Áö¹æ¾à
  • masking agent
    Â÷ÆóÁ¦
  • mucolytic agent
    Á¡¾×¿ëÇØÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antifoaming agent =defoaming a.
    ¼ÒÆ÷Á¦(á¼øÜð¥).
  • antifungal agent
    1. Ç×Áø±Õ¾à. 2. Ç×Áø±Õ¹°Áú. 3. Ç×Áø±ÕÀÎÀÚ. 4. Ç×°õÆÎÀ̾à.
  • antifungal agent
    1. Ç×Áø±Õ¾à. 2. Ç×Áø±Õ¹°Áú. 3. Ç×Áø±ÕÀÎÀÚ. 4. Ç×°õÆÎÀ̾à.
  • antifungal agent
    Ç×Áø±Õ¾à, Ç×Áø±Õ¹°Áú, Ç×Áø±ÕÀÎÀÚ.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antiinflammatory agent
    ¼Ò¿°Á¦
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimycotic agent
    Ç×Áø±Õ¾à(ù÷òØÐ¶å·).
  • antineoplastic agent
    Ç×Á¾¾çÁ¦.
  • antineoplastic agent
    Ç×Á¾¾ç¼º¹°Áú
  • antiparasympathetic agent
    Ç׺α³°¨½Å°æ(¼º)¾à(ù÷ÜùÎßÊïãêÌè(àõ)å·£©.
  • antiplatelet agent
    Ç×Ç÷¼ÒÆÇÁ¦(ù÷úìá³÷ùð¥).
  • antituberculous agent
    Ç×°áÇÙ¾à(ù÷Ì¿ú·å·).
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • minimum blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • thought blocking
    »ç°íÂ÷´Ü(ÞÖÍÅó´Ó¨).
  • vagal blocking
    ¹ÌÁֽŰæÂ÷´Ü(¡­ó´Ó¨).
  • addition agent
    ÷°¡Á¦(ôÕÊ¥ð¥).
  • agent
    ¾à¹°<Á¦>, ÀÛ¿ë¹°Áú(íÂéÄÚªòõ), º´ÀÎ(Ü»ì×).
  • agent, etiologic
    ¿øÀÎü
  • agent, infectious
    °¨¿°Ã¼, °¨¿°¿ø
  • agent, mutagenic
    µ¹¿¬º¯ÀÌ¿ø
  • alkylating agent
    ¾ËųȭÁ¦, ¾Ëųȭ¾à¹°.
  • alkylating agent
    ¾Ëųȭ ¾à¹°(¡­ûù å·Úª), ¾ËųȭÁ¦(¡­ûùð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DTIC Dimethyl Triazeno Imidazole Carboxamide
  ; Alkylating Agent
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
AAA abdominal aortic aneurysm/aneurysmectomy; acne-associated arthritis; acquired aplastic anemia; acute...
AAC antibiotic-associated [pseudomembranous] colitis; antimicrobial agent-induced colitis; augmentative ...
AAT Aachen Aphasia Test; academic aptitude test; alanine aminotransferase; alkylating agent therapy; alp...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AR 1-Adrenergic receptor
alpha(2)-AR alpha(2B)-adrenergic receptor
AR Alpha1-adrenergic receptors
alpha1-ARs Alpha1-adrenergic receptors
beta 2AR Beta 2-adrenergic receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bulking agent
    ÃæÀüÁ¦
  • carcinoclastic agent
    Á¦¾Ï ¾à, Ç×¾Ï ¾à
    µ¿ÀǾî=carcinostatic agent.
  • carcinostatic agent
    Á¦¾Ï ¾à
    ¾Ï ¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ¼ºÁúÀ» °¡Áø ¾à¹°.
  • cardioactive agent
    ½É ÀÛ¿ë ¾à, ½ÉÀå ÀÛ¿ë ¾à
    ½ÉÀå¿¡ ´ëÇÑ ÀÛ¿ë È¿°ú ¶Ç´Â Ȱ¼º È¿°ú¸¦ °¡Áö´Â ¾à¹°.
  • cariogenic agent
    ¿ì½Ä À¯¹ß ¿äÀÎ
  • causative agent
    º´¿øÃ¼, ¿øÀÎ ¹°Áú
  • chelating agent
    ŰÀÏ·¹ÀÌÆ® ¾à, ų·¹ÀÌÆ®Á¦
    ±Ý¼Ó À̿°ú °áÇÕÇÏ¿© È­ÇÕ¹°À» »ý¼ºÇÏ´Â ´Ù ¹èÀ§ÀÚ¸¦ °®´Â È­ÇÐ ¹°Áú.
  • chemotherapeutic agent
    È­ÇÐ ¿ä¹ýÁ¦
  • competitive agent
    °æÇÕÁ¦
  • compounding agent
    ¹èÇÕÁ¦, Á¶ÇÕÁ¦
    µ¿ÀǾî=com
  • contraceptive agent
    ÇÇÀÓÁ¦
  • cooling agent
    ³Ã°¢Á¦
  • coupling agent
    °áÇÕÁ¦, Ä¿ÇøµÁ¦
    ·¹Áø ±âÁú°ú ÇÊ·¯ÀÇ »çÀÌ¿¡ Á¸ÀçÇÏ¿© ¾çÀÚ¸¦ È­ÇÐÀûÀ¸·Î °áÇÕ½Ã۰í, Á¢Âø È¿°ú¸¦ ³ôÀÌ´Â ¹°Áú. ÀϹÝÀûÀ¸·Î ½Ç¶õÁ¦°¡ ÀÌ¿ëµÇ°í ÀÖ´Ù.
  • cross linking agent
    °¡±³Á¦
    ¼±»ó °íºÐÀÚÀÇ ºÐÀÚ°£À» È­ÇÐÀûÀ¸·Î °áÇÕÇϰí, ±×¹° ±¸Á¶¸¦ ¸¸µå´Â ÀÛ¿ëÀ» °®´Â ¹°Áú.
  • cryoprotective agent
    µ¿ÇØ º¸È£ ¾à
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
agent, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born.
(12 Dec 1998)
alkylating agent <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells.
Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan.
(29 Sep 1997)
antianxiety agent A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam).
Synonym: anxiolytic, minor tranquilliser.
(05 Mar 2000)
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
antinematodal agent Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
(12 Dec 1998)
antineoplastic agent Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells.
(12 Dec 1998)
antineoplastic agent, alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood.
(12 Dec 1998)
antineoplastic agent, combined The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
(12 Dec 1998)
antineoplastic agent, hormonal Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á